Researchers said that the drug used to reduce blood pressure within a system of nerves and swelling can effectively treat the potentially life-threatening situation of the liver, researchers say including o
ne of the Indian origins.
Studies on mice have shown that the portal associated with the disease of sivelestat cirrhosis and other chronic liver can reduce hypertension – thereby improving symptoms and its consequences.
Portal hypertension is a condition where the pressure inside the portal vein carrying blood from the veins of the stomach to the liver increases.
While there are therapies to treat some forms of liver diseases, including hepatitis C and autoimmune hepatitis, options have been limited for treating portal hypertension.
Vijay Shah, a gastroenterologist of the Mayo Clinic in the US, said, "Sivelestat has been used safely in humans with severe lung injury and bronchoplomonic dysplasia, in patients with Sieve and similar medicines, in patients with high levels of liver disease. A potential means of reducing is made. "
The study, published in the journal Gastroenterology, showed deposits of a blood clot-causing protein contributed to portal hypertension.
Fibrin was formation by inflammatory cells known as neutrophils, which when slowed by sivelestat were able to decrease portal hypertension.
"The study paved the way for the development of new compounds to regulate inflammation of the liver, operated by the mechanical mechanisms and for the revival of existing compounds," said Morias Hillshire, a researcher at Varsity.
Although this study was obtained from the model of the mouse, it was confirmed in lever samples from humans
